193 related articles for article (PubMed ID: 26792486)
1. No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
Cobelens F; Gebhard A; van den Hof S
Int J Tuberc Lung Dis; 2016 Feb; 20(2):282. PubMed ID: 26792486
[No Abstract] [Full Text] [Related]
2. In reply.
Takiff H; Alame-Emane AK; Pierre-Audigier C; Gicquel B
Int J Tuberc Lung Dis; 2016 Feb; 20(2):282-3. PubMed ID: 26792487
[No Abstract] [Full Text] [Related]
3. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Alame-Emane AK; Xu P; Pierre-Audigier C; Cadet-Daniel V; Shen X; Sraouia M; Siawaya JF; Takiff H; Gao Q; Gicquel B
Int J Tuberc Lung Dis; 2015 Jun; 19(6):679-84. PubMed ID: 25946359
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
Pierre-Audigier C; Surcouf C; Cadet-Daniel V; Namouchi A; Heng S; Murray A; Guillard B; Gicquel B
Int J Tuberc Lung Dis; 2012 Feb; 16(2):221-3, i-ii. PubMed ID: 22236923
[TBL] [Abstract][Full Text] [Related]
5. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
6. Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan.
Chien JY; Lai CC; Tan CK; Yu CJ; Hsueh PR
Clin Infect Dis; 2013 Apr; 56(7):1054-5. PubMed ID: 23175554
[No Abstract] [Full Text] [Related]
7. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
Whitfield MG; Streicher EM; Dolby T; Simpson JA; Sampson SL; Van Helden PD; Van Rie A; Warren RM
Tuberculosis (Edinb); 2016 Jul; 99():128-130. PubMed ID: 27450014
[TBL] [Abstract][Full Text] [Related]
8. Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.
Morales Pérez C; Gomez-Pastrana D; Aragón Fernández C; Pérez Escolano E
Arch Bronconeumol (Engl Ed); 2019 Jul; 55(7):388-390. PubMed ID: 30635203
[No Abstract] [Full Text] [Related]
9. Pyrazinamide resistance among drug-resistant Mycobacterium tuberculosis isolates at a referral hospital.
Arora J; Sidiq Z; Visalakshi P; Bhalla M; Behera D; Myneedu VP
Diagn Microbiol Infect Dis; 2013 Dec; 77(4):380-1. PubMed ID: 24075630
[No Abstract] [Full Text] [Related]
10. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Zignol M; Dean AS; Alikhanova N; Andres S; Cabibbe AM; Cirillo DM; Dadu A; Dreyer A; Driesen M; Gilpin C; Hasan R; Hasan Z; Hoffner S; Husain A; Hussain A; Ismail N; Kamal M; Mansjö M; Mvusi L; Niemann S; Omar SV; Qadeer E; Rigouts L; Ruesch-Gerdes S; Schito M; Seyfaddinova M; Skrahina A; Tahseen S; Wells WA; Mukadi YD; Kimerling M; Floyd K; Weyer K; Raviglione MC
Lancet Infect Dis; 2016 Oct; 16(10):1185-1192. PubMed ID: 27397590
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era.
Nusrath Unissa A; Hanna LE
Tuberculosis (Edinb); 2017 Jul; 105():96-107. PubMed ID: 28610794
[TBL] [Abstract][Full Text] [Related]
12. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Fofana MO; Shrestha S; Knight GM; Cohen T; White RG; Cobelens F; Dowdy DW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956422
[TBL] [Abstract][Full Text] [Related]
13. State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.
Chiang CY
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1319. PubMed ID: 19861001
[No Abstract] [Full Text] [Related]
14. [Trends in tuberculosis treatment duration].
Veziris N; Aubry A; Truffot-Pernot C
Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
[TBL] [Abstract][Full Text] [Related]
15. Fluoroquinolone resistance in Mycobacterium tuberculosis. What have we learnt?
Yew WW; Lange C
Int J Tuberc Lung Dis; 2014 Jan; 18(1):1-2. PubMed ID: 24365543
[No Abstract] [Full Text] [Related]
16. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolones resistance in multidrug-resistant tuberculosis in Pakistan and suitability of guidelines recommended standardized regimen.
Ahmad N; Khan AH; Syed Sulaiman SA; Javaid A
Int J Mycobacteriol; 2015 Sep; 4(3):258-9. PubMed ID: 27649876
[No Abstract] [Full Text] [Related]
18. Advances in the treatment of tuberculosis.
Zhang Y
Clin Pharmacol Ther; 2007 Nov; 82(5):595-600. PubMed ID: 17898708
[TBL] [Abstract][Full Text] [Related]
19. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
Velásquez GE; Calderon RI; Mitnick CD; Becerra MC; Huang CC; Zhang Z; Contreras CC; Yataco RM; Galea JT; Lecca LW; Murray MB
Antimicrob Agents Chemother; 2016 Nov; 60(11):6766-6773. PubMed ID: 27600032
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant tuberculosis in military recruits.
Freier G; Wright A; Nelson G; Brenner E; Mase S; Tasker S; Matthews KL; Bohnker BK
Emerg Infect Dis; 2006 May; 12(5):760-2. PubMed ID: 16704832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
